嘉藝控股(01025.HK)擬按“2供1”基準發行3.12億股 總籌8580萬港元
格隆匯12月20日丨嘉藝控股(01025.HK)發佈公吿,董事會建議透過供股籌集所得款項總額最多約8580萬港元(未計開支),方法為按合資格股東於記錄日期每持有2股現有股份獲發1股供股股份的基準發行3.12億股供股股份,作價每股供股股份0.275港元。假設於記錄日期或之前,已發行股份數目概無任何變動,則供股所得款項淨額(扣除估計開支後)估計最多約為8450萬港元。
自2022年1月13日(星期四)上午九時正起,股份於聯交所買賣的每手買賣單位將由4000股股份更改為8000股股份。公司將為買賣不足一手的股份提供對盤服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.